CK19和Ccnd1mRNA联合检测在乳腺癌诊断中的临床研究  

Study on the Combined Detection of CK19 and Ccnd1 mRNA Expression in the Diagnosis of Breast Cancer

作　　者：邓君[1] 黄文方[1] 饶绍琴[1] 

机构地区：[1]四川省医学科学院四川省人民医院检验科,成都市610072

出　　处：《中国肿瘤临床》2010年第18期1042-1044,共3页Chinese Journal of Clinical Oncology

基　　金：2007年四川省杰出青年基金资助(编号:2007-5-345)~~

摘　　要：目的:建立荧光定量聚合酶链反应(FQ-PCR)法检测细胞角蛋白19(CK19)和细胞周期蛋白D1(Ccnd1)基因表达水平,探讨其联合检测在乳腺癌诊断和治疗监测中的应用。方法:建立FQ-PCR法,并以β2-微球蛋白为内对照测定15例健康女性体检者、30例良性乳腺疾病患者和81例乳腺癌患者外周血中CK19和Ccnd1的表达量。结果:正常对照组、良性乳腺疾病和乳腺癌组CK19表达水平分别为(1.42±0.12,1.46±0.11,3.29±2.12)×10^(-3),Ccnd1表达水平分别(1.44±0.11,1.46±0.10,3.76±0.39)×10^(-3),两种基因表达水平在正常对照组和良性乳腺疾病组间无显著性差异(P>0.05),乳腺癌组均高于前两组(P<0.05),β_2-微球蛋白在三组间差异无显著性意义(P>0.05)。81例乳腺癌患者中CK19和Ccnd1的阳性数分别为44例和41例,阳性率分别为54.3%和40.7%,良性乳腺疾病组阳性数为0。CK19和Ccnd1联合检测的阳性数49例,阳性率为60.5%,两者联合检测的灵敏度高于单个基因的检测。结论:FQ-PCR技术是高度灵敏、高度特异的快速定量检测CK19和Ccnd1方法,两者联合检测可有效提高对乳腺癌诊断的灵敏度。Objective： To evaluate combined detection of CK19 and CCND1 genes in the diagnosis of breast cancer. Methods： FQ-PCR was used to detect CK19 and CCND1 mRNA expression in clinical samples from 81 patients with breast cancer, 30 patients with benign breast disease and 15 healthy women. 132-microglobin was used as an internal control. Results： The expression levels of CK19 and CCND1 were relatively higher in patients with breast disease than in healthy women or patients with benign disease （P〈0.05）. CK19 mRNA levels in healthy women and patients with benign and breast disease were （1.42±0.12, 1.46±0.11, 3.29±2.12） ×10 3, respectively, CCND1 mRNA levels were （1.44±0.11, 1.46±0.10, 3.76±0.39） × 10-3, respectively. No significant difference was found in CK19 and CCND1/132-microglobin between normal controls and the benign breast disease group （P〉0.05）. No difference was found in 132-microglobin among the 3 groups （P〉0.05）. Of the 81 breast cancer patients, 44 （54.3%） were positive for CK19 and 41 （40.7 %） were positive for CCND1. None of the patients with benign breast disease were positive for CK19 and CCND1. The number of patients with positive results in combined detection of CK19 and CCND1 was 49 （60.5%）. The sensitivity of combined detection of CK19 and CCND1 gene expression was higher than that of single gene detection. Conclusion： FQ-PCR is a rapid, sensitive and specific method for measuring CK19 and CCND1 levels. This combined detection can improve sensitivity of diagnosis in breast cancer.

关 键 词：荧光定量聚合酶链反应 细胞角蛋白19 细胞周期蛋白D1 乳腺癌 

分 类 号：R737.9[医药卫生—肿瘤]